We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




PARP-Inhibitors Reduce Damage in Some Neurological Disorders

By LabMedica International staff writers
Posted on 20 Aug 2018
Print article
Image: In cells under duress, stress granules (in magenta) form outside of the nucleus (in blue). TDP-43 protein in green (arrow) that cannot bind to polyADP ribose (PAR) builds up in large clumps distinct from stress granules (Photo courtesy of Leeanne McGurk, University of Pennsylvania).
Image: In cells under duress, stress granules (in magenta) form outside of the nucleus (in blue). TDP-43 protein in green (arrow) that cannot bind to polyADP ribose (PAR) builds up in large clumps distinct from stress granules (Photo courtesy of Leeanne McGurk, University of Pennsylvania).
A recent study found that blocking the activity of the poly(ADP-ribose)polymerase (PARP) family of enzymes reduced the amount of harmful TDP-43 (transactive response DNA binding protein) structures in brain cells under stress and slowed or prevented development of cytoplasmic inclusions found in neurological disorders such as amyotrophic lateral sclerosis (ALS), and some forms of frontotemporal degeneration (FTD).

In ALS and FTD, cytoplasmic aggregates of hyperphosphorylated TDP-43 accumulate and co-localize with some stress granule components, but how pathological TDP-43 aggregation is transferred to the nucleus remains unknown.

Investigators at the University of Pennsylvania (Philadelphia, USA) used cell cultures and a Drosophila (fruit fly) model to show that downregulation of the enzyme tankyrase, a PAR polymerase, reducedTDP-43 accumulation in the cytoplasm and potently inhibited neurodegeneration. They established that TDP-43 non-covalently bound to PAR via PAR-binding motifs embedded within its nuclear localization sequence. PAR binding promoted liquid-liquid phase separation of TDP-43 in vitro and was required for TDP-43 accumulation in stress granules in mammalian cells and neurons. Stress granule localization initially protected TDP-43 from disease-associated phosphorylation, but upon long-term stress, stress granules eventually dissolved, leaving behind aggregates of phosphorylated TDP-43.

The investigators reported in the August 9, 2018, online edition of the journal Molecular Cell that PARP inhibitors, which stop PAR from being generated, reduced the amount of harmful TDP-43 structures localized into stress granules. This reduced TDP-43-linked pathology and neurodegeneration and could be of use therapeutically for the treatment of ALS and FTD.

“Given the lack of treatment options, we are excited by these experiments that help elucidate molecular events that could lead to new therapeutics,” said senior author Dr. Nancy Bonini, professor of biology at the University of Pennsylvania.

Related Links:
University of Pennsylvania

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.